The agreement will focus on the development of bispecifics, cell therapies and cancer vaccines
Both will identify drug targets for neurodegenerative and neuromuscular diseases
The company will gain exclusive rights to develop and commercialise obexelimab
新生收益进入开始的s lead asset targeting obesity and other cardiometabolic diseases
The transaction gives LEO access to Timber’s lead investigational candidate, TMB-001
The deal includes a CB1 blocker being developed to treat metabolic syndrome and its associated complications
The transaction expands the company’s gene therapy and hearing loss pipeline
The companies announced the original agreement covering two antibody-drug conjugates in April
The company will gain the first refusal to one of Poseida’s clinical stage programmes
Health coverage across state linesDespite a total lack of legislative wins, the new administration has made its presence felt at home and abroad
Standing out in a crowdCelltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars
The diseased organisationLike humans, organisations can be afflicted by genetic disorders that hinder performance and threaten survival but these can be understood and cured
默克和银杏生物工作室进入生物基本ring collaboration worth up to $490mThe companies partnered last year to improve Merck's active pharmaceutical ingredient manufacturing
MSD and Astex announce expansion to oncology drug discovery collaborationAstex will receive $35m upfront plus milestone payments totalling $500m per programme
TG signs $645m deal with Neuraxpharm to support international launch of MS antibodyBriumvi has already been approved in the US and EU for adults with relapsing forms of MS
Biogen to acquire Reata for approximately $7.3bnThe deal gives Biogen access to a recently launched therapy for Friedreich's ataxia
AstraZeneca’s rare disease unit to acquire Pfizer’s early-stage gene therapies for $1bnThe transaction could potentially see staff associated with the portfolio move to Alexion
Gilead expands IT partnership with Cognizant in deal worth approximately $800mIt is hoped that the collaboration will enable Gilead to bring its medicines to market faster
Astellas and PeptiDream announce protein degrader research collaborationProtein degrader drugs have been proposed as a way to address ‘undruggable’ targets
New hires at Ferring, Flexion and ImmunocoreThe latest movers in pharma
New hires at Nanoform, Leo Pharma and CalliditasThe latest movers in pharma and biotech
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMOLatest movers in pharma and biotech
New hires at Mundipharma, Sinclair Pharma and Relay TherapeuticsLatest movers in pharma
Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership teamThe latest industry movers
No results were found
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
